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Hodgkin’s disease (HD) is rarely found in itsbelow-diaphragm presentation (BDHD 5-12%).1,2 Moreover, BDHD patients are a
heterogeneous group regarding the  involvement of
peripheral, retroperitoneal and abdominal nodes
and the spleen. However, some consistent clinical
features are apparent. Compared to HD stage I
and II above the diaphragm (ADHD), BDHD
patients are older, mostly male, and present a dif-
ferent distribution of histological subtypes. It is
worth noting that up to 30% of patients with
BDHD show the disease as confined to intra-
abdominal lymph nodes (central BDHD) rather
than having it extended into inguinal-femoral
nodes (peripheral BDHD).3,4 Although many studies
dealing with this rare condition have been pub-
lished, some questions remain unanswered, in par-
ticular: (i) do patients with BDHD have a worse
outcome than those with ADHD? (ii) is current
clinical staging an adequate procedure? (iii) do
patients with central BDHD have a worse prognosis
than those with peripheral BDHD? (iv) what is the
best therapeutic strategy for BDHD? Over the last
decade, there have been a number of retrospective
reviews from single institutions.1,3-17 Due to the rari-
ty of this condition, all the published reports are
retrospective, and span for periods of up to 20
years; this makes the reports heterogeneous with
respect to diagnostic and treatment policies.
Moreover, since most of the reports come from
single institutions [third-level reference cancer cen-
ter], a selection bias cannot be ruled out. Since
1988 the GISL (Gruppo Italiano Studio Linfomi) treat-
ment policy for Hodgkin’s lymphoma has included
three prognostic categories: a) HD1: low risk
patients with early disease and no unfavorable fac-
tors; b) HD2: intermediate risk patients with early
disease presenting one or two unfavorable factors;
c) DH3: high risk cases with advanced disease or a
very unfavorable presentation. BDHD has been
Background and Objective. Infradiaphragmatic
Hodgkin’s disease is rare, making up 5-12% of
cases in clinical stages I and II; consequently, sever-
al questions concerning prognosis and treatment
strategy remain to be answered. The aim of this
study was to analyze the clinical and prognostic
characteristics and outcome of this condition.
Methods. A series of 282 patients with CS I-II
Hodgkin’s disease (HD) was investigated. In 31
patients the disease was confined below the
diaphragm (BDHD), and in the remaining above
the diaphragm (ADHD). The presenting features
and outcomes were compared in the two groups.
Results. The BDHD group was older (p
< 0.0002), had a higher frequency of males (p
< 0.08) and a different histological subtype group
distribution (p < 0.0001). Stage II BDHD patients
had a worse overall survival rate (OS) than stage II
ADHD patients (68.8% vs 86.6% at 8 years, p <
0.01) if age is not considered; patients with more
than 40 years of age, in fact, had the same survival
rates as those with ADHD. BDHD patients with
intra-abdominal disease alone had worse prognos-
tic factors and OS (p = 0.12) than patients with
inguinal-femoral nodes.
Interpretation and Conclusions. Although BDHD
patients present distinct features, they have the
same OS and relapse-free survival rate as age-
adjusted ADHD patients. According to our experi-
ence patients with stage I peripheral BDHD
respond well to radiotherapy-based regimens.
Those with stage II and or intra-abdominal disease
are more challenging; chemotherapy or a com-
bined therapy seem to be more suitable approach-
es for these patients.
©1997, Ferrata Storti Foundation
Key words: Hodgkin’s disease, clinical stage, prognostic factors
HODGKIN’S DISEASE PRESENTING BELOW THE DIAPHRAGM. 
THE EXPERIENCE OF THE GRUPPO ITALIANO STUDIO LINFOMI (GISL)
EMILIO IANNITTO,* VINCENZO ACCURSO,* MASSIMO FEDERICO,° DANIELE VALLISA,# CARLA PIERESCA,@
SEBASTIANO F. GRAVINA,* FRANCESCO DI COSTANZO,^ ROSA DI TRAPANI,* VITTORIO SILINGARDI,°
GUGLIELMO MARIANI*
*Ematologia e Centro Trapianto di Midollo, Università di Palermo; °Oncologia Medica, Università di Modena; #Divisione di
Medicina I°, Ospedale Civile Piacenza; @Istituto di Medicina Interna ed Oncologia Medica, IRCCS, Pavia; ^Unità Operativa di
Oncologia, Ospedale S. Maria, Terni; Italy
Correspondence: Dr. Emilio Iannitto, Cattedra di Ematologia e Centro Trapianto di Midollo, Azienda Universitaria Policlinico Paolo Giaccone, via del Vespro 127,
90129 Palermo, Italy. Tel. international +39.91.6554409-6554423. Fax. international +39.91.6554402. E-mail: marianig@mbox.unipa.it 
Acknowledgements: the authors wish to thank Mr. David Holmes for his help in the preparation of the manuscript.
Received June 3, 1997; accepted September 2, 1997.
ABSTRACT
677
included in our prognostic score as an unfavorable
factor. 
The aim of this study was to analyze the clinical
and prognostic characteristics as well as the out-
come of BDHD patients and compare them with
the features of the ADHD patients treated at GISL
centers from January 1988 to December 1995. This
is, to the best of our knowledge, the first prospec-
tive multicenter study in this field.
Patients and Methods
From January 1988 to December 1995, 282 previ-
ously untreated adults with clinical stage I-II, biopsy
proven HD were evaluated and registered for
prospective treatment by 19 institutions of the Grup-
po Italiano Studio Linfomi (GISL). Their ages ranged
from 16 to 79. Thirty-one patients (11%) were
recorded as BDHD in 11 different centers. Details of
staging have been previously described.18 The clinical
stage was established according to the Ann Arbor
classification, and histological subtypes were deter-
mined using Rye nomenclature.19 As suggested by
Krikorian et al.,3 patients with infradiaphragmatic
disease were classified according to the presence
(peripheral: P) or absence (central: C) of inguinal-
femoral nodes. The clinical stage routinely consisted
of the compilation of historical data, physical exam-
ination, complete blood picture, multiple biochemi-
cal analysis, chest X-rays, computerized tomography
(CT) of both chest and abdomen, and one side
bone marrow needle biopsy. All patients with the
central form, and 3 out of 17 with the peripheral
form underwent diagnostic laparoscopy (LPS) or
laparotomy (LPT) for the evaluation of an abdomi-
nal mass with or without systemic symptoms. No
patient was splenectomized. All the tests performed
for the staging procedure were repeated after thera-
py, with the exception of the bone marrow biopsy.
According to the GISL treatment policy, on the
basis of their presenting features, patients were allo-
cated into three different prognostic groups: a) low
risk (HD1): patients in this group were treated with
radiotherapy-oriented regimen;18 b) intermediate risk
(HD2): this group received chemotherapy plus IF
radiotherapy;20,21 c) high risk (HD3): patients were
treated with aggressive ten-drug chemotherapy.22
Radiotherapy (RT) was administered by megavolt-
age equipment in 13 different RT divisions. The rec-
ommended dose was 36-38 Gy for the patients who
also received chemotherapy, and 40-44 Gy when no
chemotherapy was administered. Subtotal nodal
irradiation (STNI) was: 1) for ADHD patients, a
mantle field treated to a total dose of 4000-4500
cGy, followed by treatment of para-aortic and
splenic pedicle nodes and treatment of the spleen at
a dose of 3600 cGy, 2) for BDHD patients, a com-
plete inverted Y-field including spleen. The median
follow-up was 34 months (range 4-111) for ADHD
and 53 months (range 3-89) for BDHD. The overall
survival (OS) and relapse-free survival (RFS) curves
were calculated using the method of Kaplan and
Meier.23 Death due to causes other than HD or ther-
apy were not considered. Statistical significance was
evaluated by the log-rank test.
Results
Clinical features, histology, stage, treatment and
outcome of individual patients with BDHD are
shown in Table 1. There were 21 males and 10
females with a mean age of 49.9 (range 16-79).
Fourteen patients (45%) presented intra-abdominal
disease, which was often accompanied by fever.
Eight patients had stage I disease and 23 patients
had stage II. Mixed cellularity was the most com-
mon histological subtype, accounting for 45% of
cases. Three patients (9.6%) showed involvement of
the spleen, and all of them belonged to the C-
BDHD group (21.4%). Two C-BDHD patients were
not evaluable for response because of early death.
One patient who was treated with complete invert-
ed Y RT relapsed after 6 months in the supraclavic-
ular area and was then successfully retreated with
mini mantle radiotherapy. Seven patients belonging
to the BDHD group have died so far, two from the
peripheral and five from the central group. 
In the peripheral group, 1 died of adenocarcinoma
with an unknown primary site (see record #18) and
1 of accidental causes (see record #6). In the central
group one death was therapy related (see record
#2: gastrointestinal bleeding due to thrombocy-
topenia during chemotherapy) and 1 patient (see
record #1) died of progressive disease. The other
three deaths were caused by infection (meningitis:
record #3; sepsis: record #4; post-transfusion ful-
minant viral hepatitis: record #9) in patients in par-
tial remission or progressive disease. The clinical
characteristics at presentation and the therapy and
survival of BDHD patients with and without
involvement of inguinal-femoral nodes are com-
pared in Table 2. 
The C-BDHD group had significantly lower perfor-
mance status, hemoglobin and albumin levels, but
higher ESR values and incidence of B symptoms.
However, no difference in median age, bulky disease
or number of Ann Arbor involved areas or histologi-
cal subtype distribution was found. More patients in
the BDHD group received ten-drug chemotherapy,
showing a statistically significant difference (p
< 0.007). However, the overall survival of these
patients was not worse than that of the P-BDHD
group, although there was a trend (p= 0.12) due to
the small number of patients (Figure 1). 
In Table 3, the clinical characteristics of ADHD
and BDHD patients are compared. Patients pre-
senting BDHD were significantly older (49.9 vs 30.8
p < 0.0002) and were mostly males (p=0.08).
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Moreover, histological subtype distribution showed
an overall significant difference, as did albumin
(cut-off 4 g/dL, p = 0.002). No difference in stage
distribution was observed, though a higher percent-
age of patients in the BDHD group presented B
symptoms. The frequency of bulky disease, number
of Ann Arbor involved areas, ESR values and
response rate were similar in the two groups. The
ADHD and BDHD patients spread evenly over the
GISL risk groups, receiving low risk (HD1) RT based
treatment, intermediate risk (HD2) standard
chemotherapy and IF RT, and high risk (HD3)
aggressive ten-drug polichemotherapy. OS of
BDHD was different from that of ADHD patients
(72.6% vs 88.8% at 8 years, p < 0.003) (Figure 2).
However, no difference in RFS curves was detected
(data not shown). 
Considering the stage, a significant difference in
the OS for stage II BDHD compared to stage II
ADHD patients became apparent (Figure 3). An 8-
year actuarial survival rate was projected for 68.8%
and 86.6% of the two groups, respectively.
However, this difference disappears when stage II
BDHD patients are compared to stage II ADHD
patients of over 40 years of age (Figure 4). The dif-
ferences in OS and RFS for stage I patients with
BDHD compared to ADHD patients were not sta-
tistically significant (data not shown).
Discussion
Although the abdomen harbors a large propor-
tion of the body’s lymphoid tissue, BDHD is exceed-
ingly rare; as a presenting feature, it accounts for no
more than 12% of stage I-II patients.3 These patients
represent a heterogeneous group regarding the
involvement of peripheral, retroperitoneal and
abdominal lymph nodes and involvement of the
spleen. In the literature, BDHD patients are report-
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Table 1. Clinical features and outcome of 31 BDHD patients
Record Sex/age Histol. Stage/Bulky Presentation LPT LPS Therapy Outcome Status Survival 
(months)
1 F/75 LD II-B/y C y HD3 PG Dead 9
2 M/58 MC II-B C y HD3 NV Dead 3
3 M/58 LD I-B/y C y HD3 PG Dead 3
4 F/56 NS II-B C y HD2 PR Dead 4
5 M/26 MC I-B/y C y HD3 CR Alive 9+
6 F/79 NS II-B P HD2 NV Dead 6
7 F/47 MC II-A/y C y HD3 CR Alive 9
8 M/37 NS II-A P HD2 CR Alive 14
9 M/34 MC II-B C y HD2 PR Dead 21
10 M/35 NS I-A P HD2 PR Lost 22
11 M/55 NS I-A P HD1 CR Alive 23+
12 M/52 MC II-A P HD2 CR Alive 24+
13 M/64 MC II-A P y HD2 CR Alive 30+
14 M/29 NS II-A P HD2 CR Alive 45+
15 M/50 MC I-A C y HD1 CR Alive 45+
16 M/50 MC II-B P HD3 CR Alive 53+
17 M/32 NS2 II-B C y HD2 CR Alive 55+
18 F/60 LP II-A P y HD1 CR Dead 65+
19 M/35 MC II-A P HD1 CR Alive 65+
20 M/31 LP II-A P HD1 CR Lost 67+
21 F/35 MC II-A C y HD1 CR Alive 67+
22 M/71 LP I -A P HD1 CR Alive 70+
23 F/71 LD I -A P HD1 CR Alive 75+
24 F/16 LD II-B C y HD3 CR Alive 75+
25 M/43 MC II-A/y P HD2 CR Alive 76+
26 M/40 LD II-B/y C y HD3 CR Alive 76+
27 F/66 MC II-B C y HD3 CR Alive 78+
28 M/17 NS II-A P HD1 CR Alive 80+
29 F/67 MC II-B/y P y HD2 CR Alive 82+
30 M/57 NS II-B P HD3 CR Alive 88+
31 M/60 MC I-A C y HD1 CR Alive 89+
679Hodgkin’s disease presenting below the diaphragm





median 52 48.6 NS
range (17-79) (16-75)
Sex M/F 13/4 8/6 NS
Symptoms B % 23.5% 64.2% < 0.03
Stage I/II 4/13 4/10 NS
PS (K.B.) 95 75 < 0.003
Follow-up
Median 53.6 33.3 NS
Range 7-88 3-89
Hb < 11 g/dL 5.9% 42.8% < 0.01
ESR > 40 18.7% 66.6% = 0.01
LDH 250 266 0.08
Albumin < 4 g/dL 40% 76.9% < 0.04
Histology
NS 7 2 0.1
LP 3 0 0.09
MC 6 8 0.2
LD 1 3 0.09
Bulky 2 5 0.2
N° involved sites 2 3 NS
CR+PR 94.1% 71.4% NS
Surv. at 8 years 80.67% 60.58% NS
Therapy
HD1 7 3 NS
HD2 8 3 NS
HD3 2 8 NS
Legend. HD1: VBM+EF RT;  HD2: ABVD+IF RT or CcVPP+EF RT; HD3:
MOPPEBVCAD; NS: not significant.





Median 49.9 31.20 < 0.0002
Range (16-79) (18-79)
Sex M/F 21/10 121/130 = 0.08
Stage I/II 8/23 51/200
Symptoms B % 42% 28% NS
PS (K.B.) 90 90
Hb < 11 g/dL 13% 26% = 0.06
ESR > 40 39% 38%
LDH 250 306
Albumin < 4 g/dL 57% 34% = 0.02
Histology
NS 9 154 < 0.004
LP 3 28
MC 14 63 < 0.01
LD 5 6 < 0.001
Bulky 7/31 68/251 NS
CR + PR 80.6% 94.5% NS
Surv. at 8 years 72.6% 88.7% < 0.003
Therapy
HD1 104 10 NS
HD2 92 11 NS
HD3 55 10 NS
Legend. HD1: VBM+EF RT;  HD2: ABVD+IF RT or CcVPP+EF RT; HD3:
MOPPEBVCAD; NS: not significant.
Figure 1. Kaplan-Meier plot of overall survival of P-BDHD com-
pared to C-BDHD patients.
Figure 2. Kaplan-Meier plot of overall survival for patients with
stage I/A-II/B ADHD and BDHD.
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ed as being predominantly male,1,5,6,13,15 older1,6,8,14
than ADHD patients, with a low frequency of NS
histology,1,3,6,13,14 and poor prognosis.8,11,16 Still, other
studies did not find any difference in median age,12,15
distribution of histology subtypes,8,10 gender8,14 or
prognosis1,7,13,14,17 when comparing BDHD and
ADHD patients of similar stages. Our knowledge
about BDHD derives from single institution retro-
spective studies with up to 20 years of observation.
Clearly, this long period of observation may have
led to pooling in the data collection of patients, as
they may have been treated under different policies.
These features may also be true for some recent
reports.4,16
In the present study we have analyzed a series of
CS I-II Hodgkin’s disease patients enrolled in
prospective trials by GISL. Moreover, infradiaphrag-
matic presentation was considered a negative prog-
nostic factor evaluated with the stage, symptom
histology and bulk in order to classify the patients
in low, intermediate or high risk groups. Therefore,
all the patients in the present analysis were subject-
ed to the same staging and treatment policy. Eleven
of all clinical stage I-II HD patients presented
abdominal nodes; patients with BDHD were older
and had NS histology less often than patients with
ADHD. While we confirmed the male predomi-
nance assessed in the literature, we did not find a
significantly different incidence of B symptoms. Of
interest, is the significant prevalence of hypoalbu-
minemia.
Spleen involvement represents an important fea-
ture of the abdominal HD presentation. In a review
of 76 BDHD patients who underwent staging
laparotomy,3 spleen involvement was documented
in 28%, but only 5% of the patients were upstaged
to stage IV because of liver involvement. Moreover,
the analysis of the combined experience of five
series reported by Liew et al.12 indicated an inci-
dence of spleen involvement of 7% (2/27) for CS
IA, 37% for CS IIA and 62% for CS IIB. We detected
spleen involvement in three patients (9.6%), all of
whom belonged to stage II C-BDHD, but this figure
is likely to be an underestimate because our
patients were staged clinically. Only 17 out of 31
underwent surgical procedures for diagnostic pur-
poses and no patient was splenectomized. We
would also stress that in our series, all those with
spleen involvement also had para-aortic disease.
The data coming from series in which lymphoan-
giography (LAG) was routinely performed reflect
the same figure.3,4,9,11 A negative LAG in patients
with inguinal-femoral disease has been correlated
with a low risk (0-10%) of splenic involvement. For
patients with a positive LAG, the corresponding risk
has ranged from 25 to 52%. Therefore, we believe
there is now enough data to consider clinical stag-
ing as an adequate approach for the majority of
peripheral BDHD cases, similarly to the policy
adopted for ADHD patients.24 This is supported by
the fact that either chemotherapy or combination
therapy is considered the therapy of choice for CS
II. For central diseases which require surgical proce-
dure for diagnostic purposes, a more conservative
approach with laparoscopy or an image-guided
core needle biopsy25 could be preferable. Indeed, in
our experience, most of these patients had B symp-
toms, a very high risk of spleen involvement, and
were therefore candidates for chemotherapy.
Recent advances in diagnostic imaging techniques,
such as Gallium 67 scintigraphy and positron emis-
sion tomography (PET), could be of value in the
near future in staging and remission evaluation of
this rare subset of HD.26 PET, particularly, offers a
Figure 3. Kaplan-Meier plot of overall survival for patients with
stage II ADHD and BDHD.
Figure 4. Actuarial survival of patients over 40 years of age with
stage II BDHD compared to that of patients with stage II ADHD.
potential advantage over Gallium 67 scintigraphy in
the abdomen, as interpretation of PET is normally
unimpeded by massive bowel excretion of radionu-
clides. A question about BDHD that remains
unanswered is whether10,16,17 or not1,7,9,13,14 this HD
presentation is associated with a worse prognosis.
Our series reveals a statistically significant decrease
in terms of OS in patients with stage II BDHD as
compared to stage II ADHD, while no differences
were shown in RFS. This difference in OS, however,
disappears when BDHD patients are compared to
ADHD patients of over 40 years of age. 
Age is a well-known adverse prognostic factor for
survival, whatever the cut-off be (40 or 50 years)27
for patients who are either clinically27 or pathologi-
cally staged.29 Thus, a negative prognosis may be
related to the age, rather than to the site of presen-
tation. It is still unclear why abdominal HD is so
frequent in elderly men. In some reports, a worse
prognosis for C-BDHD patients than for those with
initial P-BDHD has been reported.1,4,11,13,17 In our
study, C-BDHD had a higher incidence of negative
prognostic factors, namely anemia, hypoalbumine-
mia and ESR > 40 mm. Despite the fact that
patients with C-BDHD had received a more aggres-
sive treatment than P-BDHD patients (57% vs 11%
ten-drug polichemotherapy p= 001), they fared
worse in terms of OS (p = 0.12). No differences
concerning stage, bulk, number of Ann Arbor
involved areas or median age between peripheral
and central BDHD were apparent. Moreover, delay
in diagnosis did not differ between the two groups
(data not shown). We would therefore share the
opinion that the differences in the pattern of pre-
sentation and in the outcome reported are related
to the abdominal presentation itself. Roos et al.4
suggested that patients with pelvic disease, also,
should be considered differently from those with
inguinal-femoral disease, at least in terms of treat-
ment strategy, since a high failure rate occurs, when
patients are treated with limited radiotherapy.
None of our patients treated with Y Rt and VBM
chemotherapy failed to respond to treatment  or
relapsed, suggesting that this combined protocol29
may provide a good control of microscopic disease
as it has been shown for ADHD stage I-IIB.
Therefore, we share the opinion that a spread of
disease along the iliac node stations should be con-
sidered an important element for planning a more
aggressive therapeutic approach. 
In conclusion, our data indicate that BDHD is a
rare condition with distinct features and adverse
prognostic factors. Staging should be as uninvasive
as possible and, for C-BDHD, laparotomy can be
avoided. Two different groups can be distinguished
concerning the therapy: 1) patients in stage I with
inguinal-femoral disease, for whom clinical staging
and a radiotherapy based-regimen are an appropri-
ate approach; and 2) patients with stage II and/or
intra-abdominal presentation. These are a diagnos-
tic and therapeutic challenge with a higher risk of
early death, especially if the tumor is bulky. Because
of these factors, therapy for C-BDHD should
include both standard chemotherapy and involved
field radiation therapy.31 If adequately treated, the
outcome of these patients is similar to that of
patients of comparable age and different presenta-
tion site. 
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